# US biotech Oblenio Bio raises US$62m Series B for an autoimmune T-cell engager optioned from China's Leads Biolabs
> Pfizer Ventures leads with Deep Track, GV and Aditum; the asset LBL-051 comes from Nanjing's Leads Biolabs, another China-discovered drug advanced through a US company

**Meta:** type: event · date: 2026-06-25 · heads: أموال من, اللعبة الطويلة · 5 takes · 2 lenses · 2 regions

## Summary

[Oblenio Bio](/ar/entity/biotech-vc) closed an oversubscribed US$62m Series B on 25 June 2026, led by [Pfizer Ventures](/ar/entity/pfizer) with Deep Track Capital, GV and founding investor Aditum Bio. Its lead asset, LBL-051, is a CD19xBCMAxCD3 tri-specific T-cell engager meant to reset the immune system in severe autoimmune disease. Oblenio holds an exclusive option to a global license for the drug from [Leads Biolabs](/ar/entity/leads-biolabs) of Nanjing, [China](/ar/entity/china), which announced the round in parallel. Preclinical primate data presented at EULAR 2026 showed complete B-cell and plasma-cell depletion without cytokine release syndrome. Proceeds fund initial clinical development.

## The split

US biopharma coverage frames Oblenio through the competitive autoimmune T-cell-engager race and Pfizer Ventures' bet. The Chinese partner's own release foregrounds Leads Biolabs as the discoverer, a reminder that the molecule is Chinese science advanced by a US company. The pattern, Western venture funding a NewCo built around a China-originated asset, is now common enough that both sides publicise their half of it.

## By the numbers

- US$62m, oversubscribed Series B.
- LBL-051, a CD19xBCMAxCD3 tri-specific T-cell engager.
- EULAR 2026, where preclinical primate data were shown.
- Pfizer Ventures, Deep Track, GV, Aditum Bio, the syndicate.
- June 25, 2026, announced.

## Why it matters

Cross-border licensing is reshaping biotech: Chinese labs increasingly discover assets that US-domiciled companies raise Western capital to develop and commercialise. Oblenio is a clean case, and its progress will test both the autoimmune T-cell-engager thesis and the durability of US-China drug-licensing pipelines as scrutiny of such deals grows in Washington.

## What to watch

- Whether Oblenio exercises the full Leads Biolabs license and enters the clinic on schedule.
- US political scrutiny of China-originated drug assets.
- Competing autoimmune T-cell engagers from larger players.

## Regional takes (batched by bias / lens)

### unlabelled
- **GlobeNewswire (Oblenio Bio)** (United States, en) — Company release: US$62m Series B led by Pfizer Ventures; Oblenio holds an exclusive option to a global license for LBL-051, a CD19xBCMAxCD3 tri-specific T-cell engager, from Leads Biolabs.
  > "Oblenio Bio closes $62 million Series B to advance tri-specific T-cell engager LBL-051."
  Source: https://www.globenewswire.com/news-release/2026/06/25/3317342/0/en/oblenio-bio-closes-62-million-series-b-to-advance-tri-specific-t-cell-engager-lbl-051-for-autoimmune-diseases-into-clinical-development.html
- **GlobeNewswire (Leads Biolabs)** (China, en) — The Nanjing partner's parallel release confirming LBL-051's origin on the Leads Biolabs platform and the option agreement behind Oblenio's raise.
  > "Leads Biolabs announces partner Oblenio Bio's $62 million oversubscribed Series B."
  Source: https://www.globenewswire.com/news-release/2026/06/25/3317381/0/en/leads-biolabs-announces-partner-oblenio-bio-s-62-million-oversubscribed-series-b-financing-to-advance-tri-specific-t-cell-engager-lbl-051-for-autoimmune-diseases-into-clinical-deve.html
- **Fierce Biotech** (United States, en) — 
  Source: https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-26
- **BioSpace** (United States, en) — 
  Source: https://www.biospace.com/press-releases/oblenio-bio-closes-62-million-series-b-to-advance-tri-specific-t-cell-engager-lbl-051-for-autoimmune-diseases-into-clinical-development

### biopharma industry
- **Endpoints News** (United States, en) — Industry read on the raise, the Leads Biolabs origin and the crowded autoimmune T-cell-engager field, part of a wave of Chinese-discovered assets advanced by US NewCos with Western venture money.
  > "Autoimmune disease company Oblenio Bio clinches $62M in Series B."
  Source: https://endpoints.news/autoimmune-disease-company-oblenio-bio-clinches-62m-in-series-b/

## Across the graph
- Related: [[alan-series-g-2026]]
- Entities: Biotech Vc, Oblenio Bio, Leads Biolabs, Pfizer, China, United States

---
Canonical: https://rbtfl.xyz/ar/n/oblenio-bio-series-b-2026